REGENERON PHARMACEUTICALS, INC. 8-K

What Happened

• Regeneron Pharmaceuticals, Inc. filed an 8‑K on Jan. 12, 2026 to furnish a corporate update presented by Leonard S. Schleifer, M.D., Ph.D. (Board Co‑Chair, President & CEO) and George D. Yancopoulos, M.D., Ph.D. (Board Co‑Chair, President & CSO) at the 44th Annual J.P. Morgan Healthcare Conference.
• The slide deck (Exhibit 99.1) includes certain preliminary, unaudited financial information for the fourth quarter and full year 2025 and was furnished under Regulation FD.

Key Details

• Presentation date: January 12, 2026; event: 44th Annual J.P. Morgan Healthcare Conference.
• Materials furnished as Exhibit 99.1 to the Form 8‑K; cover page XBRL tags embedded (Inline XBRL).
• Company disclosed an expected acquired in‑process research & development (I&P R&D) charge for the quarter ended Dec. 31, 2025 and noted its anticipated impact on GAAP and non‑GAAP net income per diluted share for that period.
• The update references non‑GAAP net income per diluted share and explains the company’s methodology and limitations for non‑GAAP measures.

Why It Matters

• This filing signals Regeneron has updated, preliminary financial results for Q4 and full‑year 2025; investors should watch the furnished presentation for revenue, earnings and guidance details that could affect the stock.
• The disclosed acquired I&P R&D charge may materially affect GAAP earnings for the quarter; Regeneron also presents non‑GAAP figures that exclude certain items, so compare both GAAP and non‑GAAP metrics when evaluating performance.
• The presentation is preliminary and unaudited and includes forward‑looking statements and risks; investors should wait for audited financials and read the full slide deck and subsequent SEC filings for complete figures and context.